Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma: Experience from a German referral center
Authors:
- 10 February 2017
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 32 (10) , 1730-1738
Abstract
Background and Aim: Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal cancers. Several local and systemic therapies are available for patients with HCC depending on the stage of the disease. In clinical practice, treatment decision‐making, and sequencing may be very heterogeneous.Methods: In this study, we retrospectively analyzed treatment algorithms in 2101 patients with HCC treated from 2000 to 2015 at Hannover Medical School, Germany.Results: Transarterial chemoembolization was the most common initial treatment (n = 545; 25.9%), followed by resection (n = 435, 20.7%), local‐ablative procedures (n = 283, 13.5%), systemic therapies (n = 275, 13.1%), and liver transplantation (n = 52; 2.5%). Most patients were treated only once (n = 960; 59.6%). A total of 433 (26.9%) and 160 (9.9%) patients received a second line and third line treatment after recurrent or progressive disease. Patients with more than one treatment line were diagnosed at significantly earlier disease stages (P < 0.001). Using binary logistic regression, AFP ≤ 200 μg/L, albumin > 36 g/L, and small tumor size (≤50 mm) were identified as predictors of achieving more than one treatment line. Subsequent treatment stage migration to a therapy suggested for the next advanced stage occurred only in 56.9%, whereas 43.1% received treatments suggested for earlier disease stages. Only 16% of all treated patients received systemic therapy in the salvage setting.Conclusion: Most patients were treated only once, and only a minority of patients received systemic treatment. The high dropout rate for subsequent therapies needs to be considered within therapy decision‐making. There is an urgent need for prospective studies to define the best time point when to switch patients from local to systemic therapies.Keywords
This publication has 27 references indexed in Scilit:
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE StudyLiver International, 2015
- Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular CarcinomaCardioVascular and Interventional Radiology, 2014
- Hepatocellular carcinoma epidemiologyBest Practice & Research Clinical Gastroenterology, 2014
- Hepatocellular carcinomaThe Lancet, 2012
- Hepatocellular CarcinomaNew England Journal of Medicine, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002